1. Home
  2. CRVS vs NNNN Comparison

CRVS vs NNNN Comparison

Compare CRVS & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$12.92

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$10.18

Market Cap

417.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRVS
NNNN
Founded
2014
2021
Country
United States
Germany
Employees
N/A
27
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
417.8M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
CRVS
NNNN
Price
$12.92
$10.18
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$30.17
N/A
AVG Volume (30 Days)
1.2M
29.7K
Earning Date
05-07-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
48.04
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$446.57
Revenue Growth
N/A
N/A
52 Week Low
$3.96
$8.30
52 Week High
$26.95
$54.90

Technical Indicators

Market Signals
Indicator
CRVS
NNNN
Relative Strength Index (RSI) 40.93 34.92
Support Level $12.95 $8.30
Resistance Level $14.00 $30.21
Average True Range (ATR) 0.76 1.30
MACD -0.29 0.50
Stochastic Oscillator 1.46 47.03

Price Performance

Historical Comparison
CRVS
NNNN

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: